Tin tức & Cập nhật

Stereotactic body radiotherapy (SBRT) provides comparable 5-year biochemical progression-free survival (PFS) and is associated with slightly lower rates of gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional radiotherapy (RT) in Chinese patients with low- to intermediate-risk prostate cancer, according to a real-world study in Hong Kong.

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Revi, an implantable tibial neuromodulation system powered by a patient-controlled, external wearable ankle device, demonstrates durable efficacy, excellent safety profile, and high patient satisfaction in women with urgency urinary incontinence (UUI), a study has shown.

Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.